(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

"TERAPIA COMBINADA DE RADIOFÁRMACOS DIRECIONADOS A PSMA E INIBIDOR DO PONTO DE VERIFICAÇÃO"

Em AnáliseInvention PatentPCT · CA2023050110

Application data

Invention Patent "TERAPIA COMBINADA DE RADIOFÁRMACOS DIRECIONADOS A PSMA E INIBIDOR DO PONTO DE VERIFICAÇÃO" de FUSION PHARMACEUTICALS INC. — IPC A61K 39/395
Invention Patent "TERAPIA COMBINADA DE RADIOFÁRMACOS DIRECIONADOS A PSMA E INIBIDOR DO PONTO DE VERIFICAÇÃO" de FUSION PHARMACEUTICALS INC. — IPC A61K 39/395. Drawing published by the INPI in the Industrial Property Gazette.

Number

112024015395

Type

Invention Patent

Filing

01/27/2023

Publication

11/19/2024

PCT

CA2023050110

Progress at the INPI

  1. Filing01/27/23
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 01/27/2023. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 11/19/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

FUSION PHARMACEUTICALS INC.

CA

See this company's full portfolio

Inventors

N. G. (pessoa física)

US

S. M. (pessoa física)

CA

S. A. (pessoa física)

CA

Technical data

Priority claims

US

63/304,181 · 01/28/2022

Abstract

TERAPIA COMBINADA DE RADIOFÁRMACOS DIRECIONADOS A PSMA E INIBIDOR DO PONTO DE VERIFICAÇÃO. Terapias combinadas que compreendem a administração de radiofármacos direcionados ao PSMA e um ou mais inibidores de checkpoint.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Notificação de entrada na fase nacional - PCT

#1.3

11/19/2024

RPI 2811

Alteração de dados cadastrais

#1.1

08/06/2024

RPI 2796

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.